CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.09B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.73: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.97%Above 5Y avg (0.08%)
Annual Rate
CNY 0.13Paid annual
Payout Ratio
131.7%High
Last Ex-Dividend
Jun 24, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
20.66BCNY3.09B · vs all stocks (USD)
Trailing P/E
107.67xRevenue (TTM)
2.10BCNY314.15M · vs all stocks (USD)
Profit Margin
9.00%Beta
0.5690xvs all stocks
52-Week Change
11.48%vs all stocks
Market Capitalization
20.66BCNY3.09B · vs all stocks (USD)
Enterprise Value
21.12BCNY3.16B · vs all stocks (USD)
Trailing P/E
107.67xForward P/E
28.71xPrice to Sales (TTM)
9.85xPrice to Book (MRQ)
2.96xEnterprise to Revenue
10.07xEnterprise to EBITDA
38.92xGross Margin
69.16%Profit Margin
9.00%Operating Margin
-7.33%Return on Assets (TTM)
0.96%Return on Equity (TTM)
1.97%Revenue (TTM)
2.10BCNY314.15M · vs all stocks (USD)
Revenue per Share (TTM)
1.30CNYUpdated Oct 20, 2026Quarterly Revenue Growth
-43.60%Gross Profit (TTM)
1.59BCNY238.01M · vs all stocks (USD)
EBITDA (TTM)
271.56MCNY40.66M · vs all stocks (USD)
Net Income (TTM)
188.77MCNY28.26M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-43.58%Operating Cash Flow (TTM)
548.19MCNY82.07M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
122.23MCNY18.30M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1250CNYUpdated Oct 20, 2026Trailing Annual Dividend Yield
0.97%vs all stocks
5-Year Average Dividend Yield
0.08%vs all stocks
Payout Ratio
131.69%Minority Interest (Equity)
915.40MCNYFY2025 · Dec 31, 2025Revenue
2.42BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
615.25MCNYFY2025 · Dec 31, 2025Gross Profit
1.80BCNYFY2025 · Dec 31, 2025Operating Income
340.86MCNY51.03M · vs all stocks (USD)
Pre-tax Income
166.11MCNYFY2025 · Dec 31, 2025Income Tax Expense
40.96MCNYFY2025 · Dec 31, 2025Net Income
125.16MCNYFY2025 · Dec 31, 2025EBIT
163.89MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
777.89MCNYFY2025 · Dec 31, 2025Research & Development
291.88MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.01BCNYFY2025 · Dec 31, 2025Other Operating Expenses
21.28MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
67.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
-2.22MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1111CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1111CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.60BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.60BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
125.16MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
52.58MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
383.23MCNYFY2025 · Dec 31, 2025Free Cash Flow
-125.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.35BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
125.16MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-1.25MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
111.91MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
147.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-508.85MCNYFY2025 · Dec 31, 2025Sale of Investments
192.20MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-316.65MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
159.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-393.69MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.99MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.56BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.82BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.60BSharesUpdated Oct 20, 2026Float Shares
1.48BSharesUpdated Oct 20, 2026% Held by Insiders
9.58%vs all stocks
% Held by Institutions
10.11%vs all stocks
Total Cash (MRQ)
1.19BCNY178.06M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7440CNYUpdated Oct 20, 2026Total Debt (MRQ)
1.30BCNY194.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1771xCurrent Ratio (MRQ)
2.07xBook Value per Share (MRQ)
4.37CNYUpdated Oct 20, 2026Total Assets
12.07BCNY1.81B · vs all stocks (USD)
Total Current Assets
4.55BCNYFY2025 · Dec 31, 2025Total Liabilities
2.53BCNYFY2025 · Dec 31, 2025Total Non-current Assets
7.52BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
597.07MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.94BCNYFY2025 · Dec 31, 2025Cash
1.35BCNYFY2025 · Dec 31, 2025Cash Equivalents
4.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.35BCNYFY2025 · Dec 31, 2025Accounts Receivable
2.15BCNYFY2025 · Dec 31, 2025Inventory
574.16MCNYFY2025 · Dec 31, 2025Accounts Payable
1.37BCNYFY2025 · Dec 31, 2025Short-term Debt
182.55MCNYFY2025 · Dec 31, 2025Other Current Liabilities
156.17MCNYFY2025 · Dec 31, 2025Long-term Debt
206.08MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
97.80MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.60BCNYFY2025 · Dec 31, 2025Retained Earnings
2.86BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
9.54BCNY1.43B · vs all stocks (USD)
52-Week Low
10.88CNYUpdated Oct 20, 202652-Week High
16.97CNYUpdated Oct 20, 202652-Week Change
11.48%vs all stocks
Beta
0.5690xvs all stocks
50-Day MA
13.74CNYUpdated Oct 20, 2026200-Day MA
12.89CNYUpdated Oct 20, 2026Avg 10-Day Volume
95.87MSharesUpdated Oct 20, 2026Avg 30-Day Volume
84.78MSharesUpdated Oct 20, 2026Diluted EPS (TTM)
0.1200CNYUpdated Oct 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.73: safe zoneNotable
Altman Z-Score: 5.73
High earnings qualityNotable
Earnings Quality Score: 0.52
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.09B, above the global median of $1.15BNotable
Market cap (USD): 3,093,751,669.068Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Autobio Diagnostics Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dyne Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lepu Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BioArctic AB
Tier 1ProductionApproval-Gated PipelineRuleRisk